Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial

被引：0

作者：

Waidmann, O. ^{[1
]}

Abou-Alfa, G. K. ^{[2
]}

Meyer, T. ^{[3
]}

Cheng, A-L ^{[4
]}

El-Khoueiry, A. B. ^{[5
]}

Rimassa, L. ^{[6
]}

Ryoo, B-Y ^{[7
]}

Cicin, I ^{[8
]}

Merle, P. ^{[9
]}

Chen, Y. H. ^{[10
]}

Park, J-W ^{[11
]}

Blanc, J-F ^{[12
]}

Bolondi, L. ^{[13
]}

Klumpen, H-J ^{[14
]}

Chan, S. L. ^{[15
]}

Dadduzio, V ^{[16
]}

Hessel, C. ^{[17
]}

Borgman-Hagey, A. E. ^{[17
]}

Schwab, G. ^{[17
]}

Kelley, R. K. ^{[18
]}

机构：

[1] Univ Liver & Canc Ctr Frankfurt, Frankfurt, Germany

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Royal Free Hosp, London, England

[4] Natl Taiwan Univ Hosp, Taipei, Taiwan

[5] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[6] Humanitas Canc Ctr, Humanitas Clin & Res Ctr, Rozzano, Italy

[7] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[8] Trakya Univ, Sch Med, Edirne, Turkey

[9] Groupement Hosp Lyon Nord, Lyon, France

[10] Liou Ying ChiMei Hosp, Dept Med Oncol, Tainan, Taiwan

[11] Natl Canc Ctr, Goyang, South Korea

[12] CHU, Hop Haut Leveque, Bordeaux, France

[13] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[14] Univ Amsterdam, Dept Med Oncol, Acad Med Ctr, Amsterdam, Netherlands

[15] Chinese Univ Hong Kong, State Key Lab Oncol South China, Hong Kong, Hong Kong, Peoples R China

[16] UOC, Ist Oncol Veneto, IRCCS, Padua, Italy

[17] Exelixis Inc, San Francisco, CA USA

[18] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V763

引用

页码：254 / 254

页数：1

共 50 条

[41] Phase II trial of sorafenib (S) and capecitabine (C) for hepatocellular carcinoma (HCC) in cirrhotic patients (pts).
Rojas-Hernandez, Cristhiam Mauricio
Patt, Yehuda Z.
Fekrazad, M. Houman
Steinberg, Kim A.
Roach, Mary
Lee, Fa-Chyi
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[42] Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT)
Rimassa, Lorenza
Porta, Camillo
Borbath, Ivan
Daniele, Bruno
Salvagni, Stefania
Van Laethem, Jean Luc
Van Vlieberghe, Hans
Trojan, Jorg
Kolligs, Frank T.
Weiss, Alan
Barahona, Nancy
Gasbarrini, Antonio
Lencioni, Monica
Pande, Amitkumar U.
Lamar, Maria
Chen, Yinpu
Schwartz, Brian E.
Abbadessa, Giovanni
Santoro, Armando
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[43] Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
Kelley, Robin Kate
Ryoo, Baek-Yeol
Merle, Philippe
Park, Joong-Won
Bolondi, Luigi
Chan, Stephen L.
Lim, Ho Yeong
Baron, Ari D.
Parnis, Francis
Knox, Jennifer
Cattan, Stephane
Yau, Thomas
Lougheed, Julie C.
Milwee, Steven
El-Khoueiry, Anthony B.
Cheng, Ann-Lii
Meyer, Tim
Abou-Alfa, Ghassan K.
ESMO OPEN, 2020, 5 (04) : 1 - 9
[44] Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Yau, T.
Rimassa, L.
Cheng, A-L.
Park, J-W.
Braiteh, F.
Chaudhry, A.
Benzaghou, F.
Thuluvath, P.
Hazra, S.
Milwee, S.
Tan, B.
Sinha, R.
Kayali, Z. K.
Zhu, A. X.
Kelley, R. K.
ANNALS OF ONCOLOGY, 2019, 30
[45] Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Rimassa, L.
Cheng, A-L.
Braiteh, F.
Chaudhry, A.
Benzaghou, F.
Thuluvath, P.
Hazra, S.
Borgman-Hagey, A. E.
Tan, B.
Kayali, Z. K.
Zhu, A. X.
Kelley, R. K.
ANNALS OF ONCOLOGY, 2019, 30 : 320 - 320
[46] Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.
Cheng, Ann-Lii
Yen, Chia-Jui
Kim, Tae-You
Feng, Yin-Hsun
Chao, Yee
Lin, Deng-Yn
Loembe, Arsene-Bienvenu
Hocke, Julia
Choi, Caren
Ryoo, Baek-Yeol
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[47] Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial
Choueiri, T.
Escudier, B.
Powles, T.
Mainwaring, P.
Rini, B.
Donskov, F.
Hammers, H.
Hutson, T.
Roth, B.
Peltola, K.
Lee, J. L.
Heng, D.
Schmidinger, M.
Borgman-Hagey, A.
Hessel, C.
Scheffold, C.
Schwab, G.
Tannir, N.
Motzer, R.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S708 - S709
[48] Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.
Abou-Alfa, Ghassan K.
Meyer, Tim
Cheng, Ann-Lii
Cicin, Irfan
Bolondi, Luigi
Klumpen, Heinz Josef
Chan, Stephen Lam
Dadduzio, Vincenzo
Milwee, Steven
Dubey, Sarita
Kelley, Robin Kate
El-Khoueiry, Anthony B.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[49] Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).
Ciuleanu, Tudor-Eliade
Bazin, Igor
Lungulescu, Dan
Miron, Lucian
Bondarenko, Igor
Deptala, Andrzej
Rodriguez-Torres, Maribel
Giantonio, Bruce J.
Sun, Weijing
Fox, Norma Lynn
Aktan, Gursel
Wissel, Paul Stephen
Egger, Jacki
Ding, Meichun
Kalyani, Rubana
Gribbin, Matthew Joseph
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[50] Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Rimassa, L.
Cheng, A.
Braiteh, F.
Benzaghou, F.
Hazra, S.
Borgman, A.
Sinha, R.
Kayali, Z.
Zhu, A.
Kelley, R.
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 5 →